All News

Scott Nelson, PharmD, MS, FAMIA, ACHIP, discussed the increasingly crucial role artificial intelligence has played in streamlining pharmacy services.

Researchers analyzed liveborn infant data from January 2020 to June 2024 to determine prevalence, cause, and treatment strategies for pain among preterm infants.

Ozempic is now the most broadly indicated glucagon-like peptide-1 receptor agonist across the pharmaceutical drug market.

A supratherapeutic dose of 1000 ug cebranopadol was significantly less likeable compared to 40 mg oxycodone when crushed and taken intranasally.

Researchers conducted a literature review of patients’ clinical experiences with using secukinumab to treat psoriatic arthritis.

Researchers analyzed overall prescription stimulant dispensing trends among US children from 2017 to 2023.

Eric Tichy, PharmD, MBA, BCPS, FCCP, FAST, sat down with Drug Topics to discuss challenges within the business behind health-system pharmacies.

Among a population of patients with type 2 diabetes, researchers assessed the similarities and differences between SGLT2 inhibitors.

Heather Folz, PharmD, BCACP and Christina H. Sherrill, PharmD, BCACP, BC-ADM discuss challenges pharmacists may face when implementing CGM services and how they can help raise awareness.

Along with discount drug card company GoodRx, the suit is aimed at CVS Caremark, Express Scripts, MedImpact Healthcare Systems, and Navitus Health Solutions.

To highlight the effectiveness of pediatric obesity treatment, researchers measured its impact on morbidity and mortality in young adulthood.

Cebranopadol is a first-in-class investigational therapy that targets the nociceptin/orphanin FQ receptor and the µ-opioid receptor.

The US government is entrusting mRNA vaccine pioneers Moderna to develop protection for the gradually increasing threat of avian influenza.

Erin Fox, PharmD, MHA, BCPS, FASHP, discussed the 2025 Pharmacy Forecast and its perspective on managing ultra-high-cost drugs.

Kurt Proctor, PhD, RPh, President of the NCPA Innovation Center, discussed his organization’s efforts in launching the Independent Community Pharmacy Consortium for Government Engagement.

For adults with obesity but no diabetes diagnosis, researchers searched for the key factors leading to semaglutide initiation.

The approval makes Johnson and Johnson’s esketamine nasal spray the first and only monotherapy for the treatment of major depressive disorder in adult patients.

Jonathan Watanabe, PharmD, MS, PhD, BCGP, discussed a section of the ASHP 2025 Pharmacy Forecast that he co-authored titled “Addressing the Gap in Primary Care.”

The lawsuit alleges Walgreens has been filling prescriptions in violation of the Controlled Substances Act since 2012.

Joseph DiPiro, PharmD, FCCP, FAAAS, editor of the American Society of Health-System Pharmacists 2025 Pharmacy Forecast, discussed key themes in the forecast that will impact health-system pharmacy in 2025.

A poll conducted by the Global Healthy Living Foundation found 11% of respondents with chronic conditions do not plan to get vaccinated for flu, COVID-19 or RSV.

Researchers wanted to better understand the accuracy of advertising practices behind websites selling compounded GLP-1 RAs.

Support for and personal interest in expanded access to advance provision and over-the-counter medication abortion has increased significantly since the constitutional right to abortion was overturned by the Supreme Court.

Researchers compared the safety and reactogenicity of simultaneous doses of recombinant zoster vaccine paired with 2 separate types of inactivated influenza vaccines.

The therapy is the first and only prefilled testosterone cypionate injection approved by the FDA.

There are a lack of data available on the optimal antiviral medication for nonsevere flu.

Sarah Gray, PharmD, GAICD, explored the unique combination of being both a pharmacist and nutritionist.

RGT-075 from Regor Therapeutics demonstrated a statistically significant 5% placebo-adjusted weight loss in adult patients with obesity or overweight.